Search Result

Results for "

PARP inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (252) Adenosine Receptor (1) Adrenergic Receptor (1) Akt (8) AMPK (2) Anaplastic lymphoma kinase (ALK) (1) Androgen Receptor (3) Apoptosis (82) Arenavirus (2) ATM/ATR (1) Aurora Kinase (1) Autophagy (10) Bacterial (2) Bcl-2 Family (6) c-Met/HGFR (1) c-Myc (1) Caspase (26) CDK (10) Ceramidase (1) Cytochrome P450 (1) Deubiquitinase (3) DNA-PK (1) DNA/RNA Synthesis (5) Drug Metabolite (1) Dynamin (1) Endogenous Metabolite (12) Epigenetic Reader Domain (4) ERK (3) FGFR (1) Fluorescent Dye (1) FXR (2) Glutathione Peroxidase (1) GSK-3 (1) HDAC (5) Heme Oxygenase (HO) (2) Histone Demethylase (1) Histone Methyltransferase (2) HIV (1) HSP (3) IAP (1) IFNAR (2) IGF-1R (1) IKK (1) Influenza Virus (1) Interleukin Related (3) Isotope-Labeled Compounds (7) JNK (4) Keap1-Nrf2 (3) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (2) Microtubule/Tubulin (7) Mitophagy (5) Mixed Lineage Kinase (1) MMP (3) mTOR (1) NAMPT (1) Necroptosis (1) NF-κB (3) NO Synthase (1) Nucleoside Antimetabolite/Analog (7) P-glycoprotein (2) p38 MAPK (4) PD-1/PD-L1 (1) PERK (1) PI3K (4) Poly(ADP-ribose) Glycohydrolase (PARG) (2) PPAR (1) PROTACs (6) Proteasome (1) PSMA (1) Pyroptosis (3) RAD51 (1) Raf (1) Ras (1) Reactive Oxygen Species (5) Reference Standards (5) Reverse Transcriptase (1) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) ROR (1) ROS Kinase (1) Salt-inducible Kinase (SIK) (1) Sirtuin (1) STAT (1) Syk (2) Thymidylate Synthase (1) Topoisomerase (5) VEGFR (1) Wnt (3) Xanthine Oxidase (7) β-catenin (1)
By Research Areas:	Cancer (255) Cardiovascular Disease (10) Endocrinology (1) Infection (5) Inflammation/Immunology (26) Metabolic Disease (10) Neurological Disease (21)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Nucleosides and their Analogs (4) Nucleoside Phosphoramidites (2) I (5)

300

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

Targets Recommended: PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117889

PARP14 inhibitor H10	PARP Apoptosis	Cancer
PARP14 inhibitor H10, compound H 10, is a selective inhibitor against *PARP14* (IC₅₀=490 nM), over other PARPs (≈24 fold over PARP1). PARP14 inhibitor H10 induces caspase-3/7-mediated cell apoptosis .

HY-125218

PARP11 inhibitor ITK7 ITK7	PARP	Cancer
PARP11 inhibitor ITK7 (ITK7) is a potent and selective *PARP11* inhibitor. PARP11 inhibitor ITK7 can potently inhibit PARP11 with an IC₅₀ value of 14 nM. PARP11 inhibitor ITK7 can be used for the research of cellular localization .

HY-W156961

LS-75	PARP	Neurological Disease
LS-75 is a *PARP-1* inhibitor with blood-brain permeability and IC₅₀ value of 18 μM. LS-75 has neuroprotective activity .

HY-160409

TopBP1-IN-1	Topoisomerase Apoptosis	Cancer
TopBP1-IN-1 is a TopBP1 inhibitor. TopBP1-IN-1 has a synergistic effect with *PARP* inhibitors. TopBP1-IN-1 has antitumor activity .

HY-161431

RTx-152	DNA/RNA Synthesis	Cancer
RTx-152 traps Polθ on DNA and is an allosteric Polθ-pol inhibitor (IC₅₀: 6.2 nM). RTx-152 selectively kills HR-deficient cancer cells, and suppresses PARP inhibitor resistance in multiple genetic backgrounds, including homologous recombination (HR)-proficient cells. RTx-152 selectively kills BRCA2-null cells .

HY-176456

PARP14 inhibitor 2	PARP	Inflammation/Immunology Cancer
PARP14 inhibitor 2 (Compound 3) is an orally active and highly selective *PARP14* inhibitor with an IC₅₀ value of <30 nM. PARP14 inhibitor 2 inhibits the mono-ADP-ribosyltransferase activity of PARP14 and regulates IFN-γ and IL-4 signaling, reversing protumor macrophage polarization and inhibiting anti-tumor inflammatory responses. PARP14 inhibitor 2 is promising for research of PARP14-related diseases such as tumors, atopic dermatitis and autoimmune diseases .

HY-172806

PARP14 inhibitor 1	PARP	Inflammation/Immunology
PARP14 inhibitor 1 (compound Q22) is a selective *PARP14* inhibitor with an IC₅₀ of 5.52 nM. PARP14 inhibitor 1 also exhibits anti-inflammatory effects and a half life of 182 min in mouse liver microsomes. PARP14 inhibitor 1 can be utilized in atopic dermatitis research .

HY-10885

A-620223 succinate ABT-472	PARP	Cancer
A-620223 succinate (ABT-472) is an orally available poly(ADP-ribose) polymerase (PARP) inhibitor. A-620223 succinate (ABT-472) exhibits very good potency against the PARP-1 enzyme with a K_i value of 8 nM and an EC₅₀ value of 3 nM in whole cell assay, making it useful in cancer research .

HY-157165

Tubulin/PARP-IN-1	Microtubule/Tubulin PARP	Cancer
Tubulin/PARP-IN-1 (compound 14) is a dual PARP-tubulin inhibitor with activity against endometrial cancer. *Tubulin/PARP*-IN-1 inhibits PARP and tubulin with IC₅₀s of 74 nM (PARP1), 109 nM (PARP2), and 1.4 μM (Microtubule/Tubulin), respectively. Tubulin/PARP-IN-1 can induce apoptosis and autophagy and cause cell cycle arrest in the G2/M phase .

HY-W424851

DPQ hydrochloride 6,7-Dimethoxy-2-(1-piperazinyl)-4-quinazolinamine hydrochloride	PARP	Infection Inflammation/Immunology
DPQ hydrochloride is a blood-brain barrier permeable and selective *PARP-1* inhibitor that blocks PARP-1-mediated DNA damage repair and NAD ⁺/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ hydrochloride inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ hydrochloride can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases .

HY-13540

E7016 GPI 21016	PARP	Cancer
E7016 (GPI 21016) is an orally available *PARP* inhibitor. E7016 can enhance tumor cell radiosensitivity in vitro and in vivo through the inhibition of DNA repair. E7016 acts as a potential anticancer agent .

HY-148566

OUL232	PARP	Cancer
OUL232 is a potent inhibitor of mono-ARTs PARP7, PARP10, PARP11, PARP12, PARP14, and *PARP15. OUL232 is the most potent PARP10* inhibitor described to date (IC₅₀=7.8 nM), as well as the first *PARP12* inhibitor ever reported .

HY-157137

PARP1-IN-17	PARP Caspase Apoptosis	Cancer
PARP1-IN-17 is a *PARP-1* inhibitor (IC₅₀ = 19.24 nM for *PARP-1* and = 32.58 nM for PARP-2) and induce apoptosis. PARP1-IN-17 shows excellent anti-proliferative activity .

HY-163658

PARP-1-IN-23	PARP	Cancer
PARP-1-IN-23 (Compound I16 ) is an orally active and selective *PARP-1* inhibitor with the IC₅₀ of 12.38 nM. PARP-1-IN-23 inhibits tumor growth in vivo .

HY-170432

PARP1-IN-34	PARP	Cancer
PARP1-IN-34 (compound 30) is a selective *PARP1* inhibitor with an IC₅₀ of 0.32 nM. PARP1-IN-34 is a subnanomolar PARP1 inhibitor with >1000-fold selectivity against *PARP2* with an IC₅₀ of 326 nM. PARP1-IN-34 shows antitumor efficacy_[1].

HY-147886

PARP1-IN-11	PARP	Cancer
PARP1-IN-11 (compound 49) is a potent *PARP1* inhibitor with IC₅₀ value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .

HY-153590

PARP-1-IN-4	PARP	Cancer
PARP-1-IN-4 is a *PARP-1* inhibitor. PARP-1-IN-4 has inhibitory activity against PARP-1 with IC₅₀ value of 302 μM. PARP-1-IN-4 can be used for the research of lung adenocarcinoma .

HY-14478

UPF 1069 1 Publications Verification	PARP	Cancer
UPF 1069 is a *PARP* inhibitor, with IC₅₀s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

HY-102035

PARP-2-IN-1	PARP	Cancer
PARP-2-IN-1 is a potent and selective *PARP-2* inhibitor with an IC₅₀ of 11.5 nM.

HY-168657

PARP1/2-IN-4	PARP	Others
PARP1/2-IN-4 (compound 3) is a *PARP1/2* inhibitor .

HY-143398

PARP10/15-IN-1	PARP	Cancer
PARP10/15-IN-1 (compound 8l) is a potent inhibitor of dual inhibitor of *PARP10* and *PARP15, with IC₅₀s of 160 nM and 370 nM, respectively. PARP*10/15-IN-1 can be used for cancer .

HY-159612

PARP1-IN-28	PARP	Cancer
PARP1-IN-28 (compound 1) is a *PARP1* inhibitor. PARP1-IN-28 can be used in the study of cancer .

HY-105253

PARP-2/1-IN-2	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent *PARP* inhibitor with K_is of 2 and 5 nM against *PARP-2* and *PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP* activity .

HY-155122

PARP-1-IN-13	PARP	Cancer
PARP-1-IN-13 (Compound 19c) is a *PARP-1* inhibitor (IC₅₀: 26 nM). PARP-1-IN-13 inhibits DNA single-strand breakage repair and aggravates DNA double-strand breakage. PARP-1-IN-13 promotes the apoptosis of cancer cells through the mitochondrial apoptosis pathway .

HY-171543

PARP1-IN-37	PARP	Cancer
PARP1-IN-37 (Compound 8) is an orally active and selective poly(ADP-ribose) polymerase 1 and 2 (PARP1/2) inhibitor with an IC₅₀ value of 24 nM for PARP1. PARP1-IN-37 inhibits PARP activity in cells with an EC₅₀ value of 3.7 μM. PARP1-IN-37 is promising for research of BRCA-mutated tumors, such as breast and ovarian cancers .

HY-148754

PARP10-IN-3	PARP	Cancer
PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 1.7 μM for human PARP2 and human PARP15, respectively .

HY-164757

PARP-1-IN-32	Poly(ADP-ribose) Glycohydrolase (PARG)	Cancer
PARP-1-IN-32 (compound 15) is a poly (ADPribose) polymerase-1 (PARP-1) inhibitor. PARP-1-IN-32 can be used in cancer research .

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617

Rucaparib phosphate 40+ Cited Publications AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617A

Rucaparib 40+ Cited Publications AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-149800

PARP-1-IN-3	PARP Apoptosis Caspase	Cancer
PARP-1-IN-3, a benzamide derivative, is a potent *PARP-1* inhibitor with IC₅₀ values of 0.25 nM and 2.34 nM for PARP-1 and PARP-2, respectively. PARP-1-IN-3 induces apoptosis and arrest cell cycle at G2/M phase. PARP-1-IN-3 can be used in research of cancer .

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple *PARP1/2/6* inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-149398

PARP-1/2-IN-2	Apoptosis PARP CDK	Cancer
PARP-1/2-IN-2-IN-1 (Compound 12e) is a *PARP1/2/CDK12* inhibitor (IC₅₀: 34, 30 and 285 nM respectively). PARP-1/2-IN-2 inhibits DNA damage repair, promotes cell cycle arrest and apoptosis. PARP-1/2-IN-2 inhibits the growth of TNBC cells and TNBC xenograft tumor .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-102003

Rucaparib monocamsylate 30+ Cited Publications AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a *PARP1* inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-163492

PARP7-IN-19	PARP	Cancer
PARP7-IN-19 (compound 5a) is an inhibitor of *PARP7* ( IC₅₀ ≤10nM). PARP7-IN-19 can be used in the research area of tumors .

HY-151609

PARP7-IN-12	PARP	Cancer
PARP7-IN-12 is a potent *PARP7* Inhibitor with an IC₅₀ value of 7.836 nM. PARP7-IN-12 can be used in research of cancer .

HY-132297

PARP1-IN-5	PARP	Cancer
PARP1-IN-5 is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 can be used for the research of cancer .

HY-132297A

PARP1-IN-5 dihydrochloride 1 Publications Verification	PARP	Cancer
PARP1-IN-5 dihydrochloride is a low toxicity, orally active, potent and selective *PARP-1* inhibitor (IC₅₀ =14.7 nM). PARP1-IN-5 dihydrochloride can be used for the research of cancer .

HY-145328

PARP-1/2-IN-1	PARP	Others
PARP-1/2-IN-1 is a potent PARP-1/2 inhibitor with IC₅₀ of 0.51 nM and 23.11 nM, respectively.

HY-148753

PARP10-IN-2	PARP	Cancer
PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase *PARP10* inhibitor with an IC₅₀ of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on *PARP2* and *PARP15* with IC₅₀s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively .

HY-145749

PARPYnD	PARP	Cancer
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

HY-162114

PARP1-IN-18	PARP	Cancer
PARP1-IN-18 (compound 25) is a potent *PARP1* inhibitor with an IC₅₀ value of 2.7 nM. PARP1-IN-18 has anticancer effects .

HY-163081

PARP7-IN-17	PARP	Cancer
PARP7-IN-17 is a potent inhibitor of *PARP7* with IC₅₀ of 4.5 nM that has oral bioavailability. PARP7-IN-17 displays antitumor effect .

HY-151625

PARP-2-IN-3	PARP Apoptosis	Cancer
PARP-2-IN-3 (Compound 12) is a potent *PARP-2* inhibitor with an IC₅₀ of 0.07 μM. PARP-2-IN-3 induces apoptosis and necrosis in cancer cells. PARP-2-IN-3 shows appropriate predicted pharmacokinetic parameters and oral bioavailability .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active *PARP-1* inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting *PARP-1* in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting *PARP-1* activity in cancer .

HY-161606

PARP-1/2/7-IN-1	PARP	Cancer
PARP-1/2/7-IN-1 (compound 86) is a potent inhibitor of *PARP-1/2/7, with the IC₅₀* of ＜ 10 nM .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113432

Nudifloramide 2PY	Alkaloids Structural Classification Other disease Classification of Application Fields Source classification Disease markers Pyridine Alkaloids Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-113432R

Nudifloramide (Standard) 2PY (Standard)	Structural Classification Natural Products Source classification Endogenous metabolite	Endogenous Metabolite PARP
Nudifloramide (Standard) is the analytical standard of Nudifloramide. This product is intended for research and analytical applications. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-113352

7-Methylguanine	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
7-Methylguanine is an orally active and competitive *PARP-1* inhibitor with a K_i value of 61 μM. 7-Methylguanine is a metabolite of nucleic acids. 7-Methylguanine has anticancer activity against uterine sarcoma and colon adenocarcinoma. 7-Methylguanine is used as a probe for protein-DNA interactions .

HY-122935

Nigranoic acid	Infection Triterpenes Classification of Application Fields Terpenoids Source classification Plants Schisandraceae Disease Research Fields Schisandra chinensis (Turcz.) Baill.	HIV Reverse Transcriptase
Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits HIV-1 reverse transcriptase. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model .

HY-34431

Purine 7H-Imidazo(4,5-d)pyrimidine	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Purine is an endogenous metabolite. Purine bases are the building blocks of the nucleic acids. Purine inhibits the activation of *PARP*. Purine protects against oxidant-induced cell injury. Purine can be used in the research of cancer and nervous system diseases .

HY-N6866

Gomisin N	Structural Classification Neurological Disease Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Inflammation/Immunology Disease Research Fields Cancer	Apoptosis AMPK Akt PERK Keap1-Nrf2 Caspase PARP GSK-3 NO Synthase Interleukin Related
Gomisin N is an orally active lignan compound. Gomisin N can be isolated from Schisandra chinensis. Gomisin N induces Apoptosis in a variety of cells. Gomisin N activates AMPK, Akt, MAPK/ERK, Nrf2, caspase-3 and *PARP-1. Gomisin N inhibits* GSK3β, nitric oxide (NO), and proinflammatory cytokines (IL-1β, IL-6, TNF-α). Gomisin N has anti-inflammatory, antioxidant, anti-obesity, anti-diabetic, and anti-melanogenesis activities. Gomisin N has anti-tumor activity against cervical cancer and liver cancer. Gomisin N improves Alzheimer's disease .

HY-N15380

4,4′-Secalonic acid D	Structural Classification Xanthones Animals Source classification Phenols	PARP Reactive Oxygen Species Caspase Apoptosis Pyroptosis
4,4′-Secalonic acid D (Compound 12) is a *PARP1* inhibitor. 4,4′-Secalonic acid D induces the accumulation of ROS and DNA damage, activates the caspase-3/GSDME pathway, and triggers apoptosis and pyroptosis of tumor cells by inhibiting *PARP1*. 4,4′-Secalonic acid D has anti-tumor activity .

HY-W748509

Pipernonaline	Piper longum Linn. Structural Classification Alkaloids Piperidine Alkaloids Source classification Piperaceae Plants	Caspase Apoptosis
Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .

HY-N14161

Diazaquinomycin A	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Thymidylate Synthase Apoptosis
Diazaquinomycin A (DAQA), a diaza-anthracene antibiotic, is a thymidylate synthase inhibitor. Diazaquinomycin A (DAQA) induces DNA damage, cell cycle arrest, and apoptosis through cleaved-PARP .

HY-130073

Amorfrutin A	Structural Classification Simple Phenylpropanols Leguminosae Source classification Amorpha fruticosaL. Phenylpropanoids Plants	NF-κB Apoptosis
Amorfrutin A is the inhibition of NF-κB activation, that inhibits TNF-α-induced IκBα degradation, p65 nuclear translocation, and DNA-binding activity. Amorfrutin A promotes TNF-α-induced apoptosis in HeLa cell through promotion of caspase-3 and PARP proteolysis .

HY-Z0283

Benzamide Benzenecarboxamide; Phenylamide	Structural Classification Alkaloids Human Gut Microbiota Metabolites Classification of Application Fields Other Alkaloids Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite PARP
Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N1970

5,7-Dihydroxychromone 1 Publications Verification	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Isoflavones	Keap1-Nrf2 Arenavirus Caspase PARP
5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved *PARP* in 6-OHDA-induced SH-SY5Y cells .

HY-Z0283R

Benzamide (Standard)	Structural Classification Alkaloids Human Gut Microbiota Metabolites Other Alkaloids Source classification Endogenous metabolite	Endogenous Metabolite PARP
Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

HY-N1486R

Ursonic acid (Standard)	Triterpenes Structural Classification Ziziphus jujuba Terpenoids Source classification Plants Endogenous metabolite Rhamnaceae	Apoptosis Endogenous Metabolite NF-κB
CSRM617 (Standard) is the analytical standard of CSRM617. This product is intended for research and analytical applications. CSRM617 is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a Kd of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. CSRM617 induces apoptosis by appearance of cleaved Caspase-3 and PARP. CSRM617 is well tolerated in the prostate cancer mouse model

HY-N8508

Myrothecine A	Structural Classification Natural Products Microorganisms Source classification	Apoptosis Cytochrome P450 PARP JNK Bcl-2 Family Caspase
Myrothecine A is a trichothecene mycotoxin found in M. roridum. Myrothecine A induces apoptosis, promotes the cytochrome c release, PARP-cleavage and phosphorylation of JNK, increases Bax and cleaved caspase-3, -5, and -8 levels. Myrothecine A has anticancer activities and promotes the maturation of DC cells in the microenvironment. Myrothecine A inhibits proliferation of A549, MCF-7, HepG2, and SMMC-7721 cancer cells with IC₅₀s of 95, 70, 60, and 25 µM, respectively .

HY-N2132

Flavokawain B 2 Publications Verification Flavokavain B	Structural Classification Chalcones Monophenols Flavonoids other families Classification of Application Fields Source classification Phenols Plants Disease Research Fields Cancer	Apoptosis Caspase PARP Bcl-2 Family NF-κB PI3K Akt p38 MAPK MMP Reactive Oxygen Species
Flavokawain B (Flavokavain B) is an orally active chalcone. Flavokawain B results in activation of caspase-9, -3 and -8, cleavage of *PARP. Flavokawain B down-regulates Bcl-2* with concomitant increase in Bax level. Flavokawain B inhibits NF-κB, PI3K/Akt and MAPK signaling pathway. Flavokawain B exhibits Apoptotic effects. Flavokawain B inhibits MMP-9 and promotes ROS generation. Flavokawain B inhibits multiple tumors and inflammation .

HY-N6576

Hellebrigenin	Structural Classification Animals Classification of Application Fields Source classification Disease Research Fields Steroids Cancer	p38 MAPK ERK JNK IAP PARP Apoptosis Caspase
Hellebrigenin is an inhibitor that selectively targets the MAPK signaling pathway (ERK, p38, JNK) and XIAP, and can inhibit Akt expression and phosphorylation. Hellebrigenin can activate endogenous apoptosis pathways (such as mitochondrial membrane potential disruption, Caspase family activation, PARP cleavage), downregulate anti-apoptotic proteins (Bcl-2, Bcl-xL) and upregulate pro-apoptotic proteins (Bax, Bak). Hellebrigenin can also induce DNA double-strand breaks to activate the ATM pathway. Hellebrigenin can inhibit tumor cell proliferation and clone formation, and is mainly used in the study of oral squamous cell carcinoma, liver cancer and other cancers .

HY-N6969A

Dicentrine hydrochloride	Structural Classification Alkaloids Other Alkaloids Source classification Stephania epigaea Lo Plants Menispermaceae	Adrenergic Receptor
Dicentrine hydrochloride is a drug with anti-inflammatory and anti-cancer activity. Dicentrine hydrochloride exerts its effects by enhancing TNF-α-induced apoptosis in A549 lung adenocarcinoma cells. Dicentrine hydrochloride increases caspase-8, -9, -3 and poly(ADP-ribose) polymerase (PARP) activities. Dicentrine hydrochloride inhibits TNF-α-induced invasion and migration of A549 cells. Dicentrine hydrochloride significantly inhibited the TNF-α-activated TAK1, p38, JNK and Akt signaling pathways, and reduced the transcriptional activities of NF-κB and AP-1 .

HY-N0576

Solanesol 1 Publications Verification	Structural Classification Natural Products other families Neurological Disease Classification of Application Fields Source classification Plants Endogenous metabolite Inflammation/Immunology Disease Research Fields	Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP
Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and *PARP* cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .

HY-N1970R

5,7-Dihydroxychromone (Standard)	Structural Classification Flavonoids other families Source classification Phenols Polyphenols Plants Isoflavones	Keap1-Nrf2 Arenavirus Caspase PARP
5,7-Dihydroxychromone (Standard) is the analytical standard of 5,7-Dihydroxychromone. This product is intended for research and analytical applications. 5,7-Dihydroxychromone, the extract of Cudrania tricuspidata, activates Nrf2/ARE signal and exerts neuroprotective effects against 6-hydroxydopamine (6-OHDA)-induced oxidative stress and apoptosis. 5,7-Dihydroxychromone inhibits the expression of activated caspase-3 and caspase-9 and cleaved PARP in 6-OHDA-induced SH-SY5Y cells .

HY-N0576R

Solanesol (Standard)	Structural Classification Natural Products other families Source classification Plants Endogenous metabolite	Reference Standards Endogenous Metabolite Heme Oxygenase (HO) HSP p38 MAPK Akt Apoptosis Caspase PARP
Solanesol (Standard) is the analytical standard of Solanesol (HY-N0576). This product is intended for research and analytical applications. Solanesol is an orally active aliphatic terpene alcohol. Solanesol is mainly found in tobacco and other Solanaceae plants. Solanesol induces HO-1 and Hsp70 expression, activates p38 and Akt signaling pathways, and inhibits Apoptosis (reduces caspase-3 and *PARP* cleavage). Solanesol has antioxidant, anti-inflammatory, and neuroprotective activities. Solanesol can be used in the research of Huntington's disease, alcoholic liver disease, chronic inflammatory pain, anxiety, Alzheimer's disease, and bipolar disorder .

HY-N0805

Alisol B 23-acetate 1 Publications Verification 23-Acetylalismol B; 23-O-Acetylalisol B; Alisol B monoacetate	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Source classification Other Diseases Alismataceae Plants Disease Research Fields	Apoptosis Reactive Oxygen Species CDK MMP PARP FXR Syk
Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

HY-N0805R

Alisol B 23-acetate (Standard) 23-Acetylalismol B (Standard); 23-O-Acetylalisol B (Standard); Alisol B monoacetate (Standard)	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Terpenoids Source classification Alismataceae Plants	Reference Standards Apoptosis Reactive Oxygen Species CDK MMP PARP FXR Syk
Alisol B 23-acetate (Standard) is the analytical standard of Alisol B 23-acetate (HY-N0805). This product is intended for research and analytical applications. Alisol B 23-acetate is an orally active prototerpane-type triterpenoid. Alisol B 23-acetate can be isolated from Alisma orientalis. Alisol B 23-acetate induces Apoptosis, promotes ROS generation, downregulates CDK4/6, MMP-2/9, upregulates cleaved PARP, activates FXR and inhibits Syk. Alisol B 23-acetate has anti-inflammatory and hepatoprotective activities. Alisol B 23-acetate protects the kidney from ischemia-reperfusion injury. Alisol B 23-acetate has anticancer activity against ovarian cancer, colon cancer, lung cancer, and gastric cancer. Alisol B 23-acetate can be used in the study of atherosclerosis and allergic asthma .

Cat. No.	Product Name	Chemical Structure

HY-10162S

Olaparib-d5
Olaparib-d₅ (AZD2281-d₅) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-10162S1

Olaparib-d8
Olaparib-d₈ (AZD2281-d₈) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-10162S3

Olaparib-d4-1
Olaparib-d₄-1 (AZD2281-d₄-1) is the deuterium labeled Olaparib (HY-10162). Olaparib is a potent and orally active PARP inhibitor with IC₅₀s of 5 and 1 nM for PARP1 and PARP2, respectively. Olaparib is an autophagy and mitophagy activator .

HY-113432S

Nudifloramide-d3
Nudifloramide-d₃ (2PY-d₃) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro .

HY-Z0283S

Benzamide-15N
Benzamide- ¹⁵N is a ¹⁵N-labeled Benzamide. Benzamide inhibits poly(ADP-ribose) polymerase (PARP) .

HY-10617AS

Rucaparib-d8
Rucaparib-d₈ (AG014699-d₈ ) is deuterium labeled Rucaparib. Rucaparib (AG014699) is an orally active, potent inhibitor of *PARP* proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-16106S1

Talazoparib-d4
Talazoparib-d₄ (BMN-673-d₄) is deuterium labeled Talazoparib. Talazoparib (BMN-673) is a highly potent, orally active *PARP1/2* inhibitor.Talazoparib inhibits PARP1 and PARP2 enzyme activity with K_is of 1.2 nM and 0.87 nM, respectively. Talazoparib has antitumor activity .

HY-16106S

Talazoparib-13C,d4
Talazoparib- ¹³C,d4 is ¹³C and deuterated labeled Talazoparib (HY-16106). Talazoparib is an orally active PARP 1/2 inhibitor with Ki values of 1.2 nM and 0.87 nM for inhibiting PARP1 and PARP2 enzymatic activities, respectively. Has anti-tumor activity.

HY-W711852

Benzamide-d5

Benzamide-d₅ (Benzenecarboxamide-d₅) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .

Cat. No.	Product Name		Classification

HY-150221

DB008		Alkynes
DB008 is potent and selective *PARP16* inhibitor with an IC₅₀ value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-145749

PARPYnD		Alkynes
PARPYnD is a *PARP* enzyme photoaffinity probe (AfBP) based on the triple *PARP1/2/6* inhibitor AZ9482 (HY-119653), which induces breast cancer Formation of multipolar spindles (MPS) in cells. PARPYnD inhibits PAPR wih IC₅₀ of 38 nM (PARP1), 6 nM (PARP2), 230 nM (PARP6), respectively. PARPYnD enriches recombinant PARP6 incorporated into cell lysates and inhibits PARP6 in cell-free assays, but it does not label PARP6 in intact cells .

Cat. No.	Product Name		Classification

HY-W141392

2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite		Nucleoside Phosphoramidites I
2'-Fluoro-5'-O-DMT-2'-deoxyinosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-W392836

2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite		Nucleoside Phosphoramidites I
2'-O-Methyl-5'-O-dmt-inosine-3'-CE-phosphoramidite is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-152696

6-O-Methylinosine		Nucleosides and their Analogs I
6-O-Methylinosine is a hypoxanthine analogue. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154017

2′-C-Methyl-6-O-methylinosine		Nucleosides and their Analogs I
2′-C-Methyl-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-154393

2-Chloro-2'-deoxy-6-O-methylinosine		Nucleosides and their Analogs I
2-Chloro-2'-deoxy-6-O-methylinosine is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

HY-152678

6-Methoxypurine-9-β-D-5’(R)-C-methylriboside		Nucleosides and their Analogs
6-Methoxypurine-9-β-D-5’(R)-C-methylriboside is a hypoxanthine analog. Hypoxanthine is a kind of purine base mainly present in muscle tissue. And it is a metabolite produced by purine oxidase acting on xanthine. Hypoxanthine has typical anti-inflammatory effects and is a potential endogenous poly(ADP-ribose) polymerase (PARP) inhibitor. It is cytoprotective by inhibiting PAPR activity, inhibiting peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Hypoxanthine can also be used as an indicator of hypoxia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks